ingle-arm, phase II, prospective study of perioperative treatment of resectable HCC with high-risk recurrence factors
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Lenvatinib (Primary) ; Tislelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 27 Feb 2024 New trial record
- 20 Jan 2024 Results presented at the 2024 Gastrointestinal Cancers Symposium